Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
12.40
-0.45 (-3.50%)
At close: May 23, 2024, 4:00 PM
12.41
+0.01 (0.08%)
After-hours: May 23, 2024, 5:15 PM EDT

Company Description

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally.

It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform.

In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products.

Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics logo
Country United States
Founded 2015
IPO Date Sep 21, 2018
Industry Biotechnology
Sector Healthcare
Employees 100
CEO Michael Rossi

Contact Details

Address:
230 Park Avenue, Suite 3350
New York, New York 10169
United States
Phone 212-847-9841
Website ymabs.com

Stock Details

Ticker Symbol YMAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001722964
CUSIP Number 984241109
ISIN Number US9842411095
Employer ID 47-4619612
SIC Code 2834

Key Executives

Name Position
Thomas Gad Founder, Chief Business Officer and Vice Chairman
Bo Kruse Executive Vice President, Secretary, Treasurer and Chief Financial Officer
Susan Smith Senior Vice President and Chief Commercial Officer
Michael Rossi Chief Executive Officer, President and Director
Joris Wiel Jan Wilms Senior Vice President and Chief Operating Officer
Dr. Torben Lund-Hansen M.Sc., Ph.D. Senior Vice President and Chief Technology Officer
Dr. Steen Lisby M.D., M.Sc. Senior Vice President and Chief Scientific Officer
Courtney Dugan Vice President of Investor Relations
Dr. Vignesh Rajah M.B.A., MBBS Senior Vice President and Chief Medical Officer

Latest SEC Filings

Date Type Title
May 21, 2024 144 Filing
May 7, 2024 10-Q Quarterly Report
May 7, 2024 8-K Current Report
Apr 29, 2024 8-K Current Report
Apr 29, 2024 ARS Filing
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Apr 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 14, 2024 8-K Current Report
Mar 6, 2024 144 Filing